Markers of amyotrophic lateral sclerosis survival and uses thereof
EP4771385A1Pending Publication Date: 2026-07-08THE METHODIST HOSPITAL +1
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- THE METHODIST HOSPITAL
- Filing Date
- 2024-08-29
- Publication Date
- 2026-07-08
AI Technical Summary
Technical Problem
Current methods for predicting survival in amyotrophic lateral sclerosis (ALS) patients are subjective and lack objectivity, leading to varying predictions of progression and survival time among individuals.
Method used
Determining the level of 4-hydroxynonenal (4-HNE) in plasma or serum samples using an assay with a solid surface antibody or antigen-binding portion, which correlates with ALS survival prognosis, allowing for the differentiation between long-term and short-term survivors.
Benefits of technology
The method provides an objective means to predict ALS survival by correlating 4-HNE levels with mean survival time and rate of disease progression, enabling tailored therapeutic approaches for ALS patients.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2024044320_06032025_PF_FP_ABST
Abstract
Provided herein are markers and uses thereof for predicting survival in amyotrophic lateral sclerosis (ALS) patients, determining impact of an ALS therapy on survival of an ALS patient, and predicting the rate of ALS progression.
Need to check novelty before this filing date? Find Prior Art